UPDATE: UBS Upgrades Abbvie (ABBV) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Abbvie, Inc. (ABBV) Tops Q2 EPS by 6c; Guides Q3 EPS to Strong Side
July 25, 2014 7:47 AM EDT(Updated - July 25, 2014 7:50 AM EDT)
Abbvie, Inc. (NYSE: ABBV) reported Q2 EPS of $0.82, $0.06 better than the analyst estimate of $0.76. Revenue for the quarter came in at $4.93 billion versus the consensus estimate of $4.7 billion.
"This was another very strong quarter for AbbVie, as we delivered sales and earnings per share above our original guidance and announced plans to merge with Shire, a strategic action that will further enhance our long-term growth prospects," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "Last month, we raised our 2014 earnings-per-share guidance, reflecting... More
